The Second Clinical Medical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Front Immunol. 2024 Mar 12;15:1364128. doi: 10.3389/fimmu.2024.1364128. eCollection 2024.
Since the approval for the treatment of melanoma in 2014, immune checkpoint inhibitors (ICIs) have revolutionized the therapy pattern across various malignancies. Coinciding with their frequent usage, their adverse effects, including fever, cannot be neglected. In the context of cancer diseases and cancer treatments, fever of unknown origin (FUO), which has long posed a challenge for clinicians in terms of diagnosis and management, brings forth new connotation and significance. In this paper review, we present the concept of ICIs-associated FUO, consider activated immune system and elevated cytokines as common mechanisms by which ICIs induce fever and various immune-related adverse events (irAEs), summarize and compare the primary etiologies of ICI-associated FUO, and compare it with conventional types of FUO.
自 2014 年批准用于治疗黑色素瘤以来，免疫检查点抑制剂（ICI）已经彻底改变了各种恶性肿瘤的治疗模式。随着它们的频繁使用，其不良反应，包括发热，不容忽视。在癌症疾病和癌症治疗的背景下，不明原因发热（FUO）长期以来一直对临床医生的诊断和管理构成挑战，因此具有新的内涵和意义。在这篇文献综述中，我们介绍了与 ICI 相关的 FUO 的概念，认为激活的免疫系统和升高的细胞因子是 ICI 引起发热和各种免疫相关不良事件（irAE）的常见机制，总结和比较了与 ICI 相关的 FUO 的主要病因，并与传统类型的 FUO 进行了比较。
